Singh Sanjay, Vijayakumar Mahalingam Rajamanickam, Dewangan Hitesh Kumar
Department of Pharmaceutical Enginnering & Technology, Indian Institute of Technology (BHU), Varanasi, India.
Curr Drug Deliv. 2018;15(9):1284-1293. doi: 10.2174/1567201815666180716112457.
Vinorelbine bitartrate (VRL) is an antimitotic agent approved by FDA for breast cancer and non-small cell lung cancer (NSCLC) in many countries. However, high aqueous solubility and thermo degradable nature of VRL limited the availability of marketed dosage forms.
The current work is focused on the development of lipid based aqueous core nanocapsules which can encapsulate the hydrophilic VRL in the aqueous core of nanocapsules protected with a lipidic shell which will further provide a sustained release.
The ACNs were prepared by double emulsification technique followed by solvent evaporation. Box Behnken Design was utilized to optimize the formulation and process variables. Thirteen batches were generated utilizing lipid concentration, surfactant concentration and homogenizer speed as dependent variables (at three levels) and particle size and encapsulation efficiency as critical quality attributes. The ACNs were characterized for particle size, zeta potential, polydispersity index (PDI), entrapment efficiency, morphology by Transmission Electron Microscopy (TEM) and in vitro release. The ACNs were further evaluated for safety against intravenous administration by haemocompatibility studies.
Results demonstrated that lipidic nanocapsules enhanced the entrapment efficiency of VRL up to 78%. Transmission Electron Microscopy revealed spherical shape of ACNs with core-shell structure. The GMS-VRL-ACNs showed that release followed Korsemeyer peppas kinetics suggesting Fickian diffusion. Moreover, the compliance towards haemocompatibility studies depicted the safety of prepared nanocapsules against intravenous administration.
ACNs were found to be promising in encapsulating high aqueous soluble anticancer drugs with enhanced entrapment and safety towards intravenous administration.
酒石酸长春瑞滨(VRL)是一种抗有丝分裂药物,已获美国食品药品监督管理局(FDA)批准,在许多国家用于治疗乳腺癌和非小细胞肺癌(NSCLC)。然而,VRL的高水溶性和热降解性限制了市售剂型的可用性。
目前的工作重点是开发基于脂质的水核纳米胶囊,该纳米胶囊可将亲水性VRL包裹在纳米胶囊的水核中,并用脂质壳进行保护,这将进一步实现缓释。
通过复乳法结合溶剂蒸发制备ACNs。采用Box-Behnken设计优化配方和工艺变量。以脂质浓度、表面活性剂浓度和匀化器速度为自变量(三个水平),粒径和包封率为关键质量属性,制备了13批产品。对ACNs的粒径、zeta电位、多分散指数(PDI)、包封率、通过透射电子显微镜(TEM)观察的形态以及体外释放进行了表征。通过血液相容性研究进一步评估了ACNs静脉给药的安全性。
结果表明,脂质纳米胶囊可将VRL的包封率提高至78%。透射电子显微镜显示ACNs呈具有核壳结构的球形。GMS-VRL-ACNs表明,其释放遵循Korsemeyer-peppas动力学,提示为菲克扩散。此外,血液相容性研究的结果表明,所制备的纳米胶囊静脉给药具有安全性。
ACNs在包裹高水溶性抗癌药物方面具有潜力,其包封率高且静脉给药安全。